Company
TOPAZIUM is committed to support medical
research with artificial intelligence (AI) based
state-of-the-art analytical tools. We have
developed a comprehensive AI engine that
utilizes multiple medical data types to assist in
the identification of new disease patterns and
the most promising therapeutic approaches in
order to attain one of the most challenging
global goals: “Health for all”.

TOPAZIUM is committed to support medical research with artificial intelligence (AI) based state-of-the-art analytical tools. We have developed a comprehensive AI engine that utilizes multiple medical data types to assist in the identification of new disease patterns and the most promising therapeutic approaches in order to attain one of the most challenging global goals: “Health for all”.

We truly believe that this new form of collective intelligence, emerged from the combination of human scientists’ skills and computers’ capabilities, can deliver an enormous data throughput that could help find answers for medical problems that are impossible to solve with “human-only” research.

The “human scientists/AI” partnership exhibits an exponentially growing synergy, which could suppress the hurdles of the current medical R&D model. This opens the door to a new R&D paradigm, with the subsequent advancement on human health research.

Topazium´s
Medical
Research
Model

Topazium has created an integrated platform able to analyze chemical, genetic, epigenetic, imaging and clinical data generated by the whole spectrum of stakeholders within the healthcare ecosystem and across different research institutions. This way, TOPAZIUM aims to assist researchers and physicians to overcome the shortcomings of the current medical research model into another with the following characteristics:

 

· An exponential R&D approach
· Processing of pooled data from multiple sources
· Based on a wealth of information and shared assets
· Lower research costs
· A global and continuous learning process
· A groundbreaking approach

TOPAZIUM’s platform is intended to support the changes needed in the medical research paradigm. Adding a global approach to the medical research flow while incorporating the appropriate AI tools will ultimately result in better disease prevention and earlier diagnosis, as well as improved, cost-effective drug development.

Insights and decisions will be data-driven and will be combined with the work of healthcare professionals, which will improve patient care standards through a truly personalized and holistic approach. In summary, this colossal common effort based on a new collective intelligence platform will exponentially improve the quality of medical research, resulting in a radical shift from the current healthcare model.

MORE INFO

TEAM

Carlos María Galmarini
Founder and CEO

Carlos María earned his Medical Degree from the University of Buenos Aires (Argentina), after which he completed an internship in clinical oncology at Marie Curie Cancer Center (Buenos Aires). He pursued two post-doctoral fellowships in oncology at Los Angeles City of Hope Cancer Center (USA) and at Léon Bérard Cancer Center (Lyon, France). He obtained his PhD in oncology and his qualification to lead research teams (HDR) at Claude Bernard Lyon-1 University (Lyon, France).

READ MORE

Carlos María practiced medicine both at the Marie Curie and Carlos G. Durand Hospitals in Buenos Aires for several years. He has also held positions as a medical researcher in oncology at Lyon Rockefeller Medical School and in Lyon-Sud Medical School (France), where he was appointed Associate Professor. In 2008 he joined PharmaMar (Madrid, Spain) as Head of Cell Biology and Pharmacogenomics, where he was in charge of drug screening, biochemistry, molecular biology and pharmacogenomics.

He has authored over 120 publications across leading international scientific journals. In recent years, he devoted his research to the application of artificial intelligence in healthcare, molecular biology and other related-medical fields, becoming a recognized expert in this discipline.

Maximiliano Lucius
CTO

Maximiliano earned his Industrial Engineering Degree from Instituto Tecnológico de Buenos Aires (Argentina) and an MBA from Universidad Torcuato Di Tella (Buenos Aires). In addition, he has obtained a certified Data Science and Big Data Analytics Degree from the Massachussets Institute of Technology (MIT). Maximiliano has started his career as head of production at L’Electricfil S.A., Buenos Aires followed by senior managerial positions at MATERflex S.A., EnerSys S.A. and Estant S.A in Buenos Aires.

READ MORE

He has later been appointed as Chief Data Scientist at Dubai’s TradeButter where he has deployed systems monitoring financial markets’ overall performance metrics. Maximiliano focuses on designing and implementing algorithms in most data science languages (including Python and C++), as well as deploying open-source machine learning frameworks.